Effects of Green Tea to Absolute Neutrophil Count, MMP-9, %VEP1, and COPD Assessment Test Scores Stable COPD Patients

Hendrastutik Apriningsih, Suradi Suradi, Yusup Subagio Sutanto


Backgrounds: Chronic obstructive pulmonary disease is the leading cause morbidity and mortality worldwide. Cigarette smoke and noxious agent causing oxidative stress activated nuclear factor-κB then increase inflammatory genes releases. Epigallocatechin-3-gallate green tea have antiiinflammatory effect which can be use as addition therapy for stable COPD.
Methods: This study aimed to analyze the effect of EGCG to absolute neutrophil count (ANC), serum MMP-9, %FEV1, and CAT score stable COPD patients. Clinical trials of experimental with pre-test and post-test design was conducted on 30 patients in Dr. Moewardi Hospital Surakarta from February-April 2017. Samples were taken by consecutive sampling divided into treatment group (n=15) received standard therapy and green tea capsule 2x500mg/day during 28 days and control group received only standard therapy (n=15). Decreased inflammation measured by ANC and serum MMP-9, improvement of obstruction measured by %FEV1, and clinic improvement measured by CAT score.
Results: There were no significant differences (P=0.135) decrease ANC treatment group (-662.45±1446.80 µL) compared control (413.79±2292.90 µL), decrease serum MMP-9 (P=0.413) treatment group (-324.34±333.56 ng/ml) compared control (-181.21±577.52 ng/ml), %FEV1 (P=0.236) treatment group (2.56±10.77), compared control (-4.30±19.12), and significant difference (P=0.034) CAT score treatment group (-1.07±1.16) compared control (-0.20±1.08).
Conclusions: The addition of green tea capsule 2x500 mg/day during 28 days was significantly lowered CAT score, decreasing ANC, serum MMP-9 and increasing %FEV1 but not significant. (J Respir Indo 2018; 38(1): 7-15)


stabel COPD, Epigallocatechin-3-gallate, absolute neutrophil count, %FEV1, CAT score

Full Text:



Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2017 report. Global Initiative for Chronic Obstructive Lung Disease, Inc. 2017. p.1-81.

Barnes P. Why more research into molecular and cellular mechanisms of copd is needed. In: Barnes P. (eds) Chronic Obstructive Pulmonary Disease, Cellular and Molecular Mechanisms. 1st edition. Boca Raton: Taylor & Francis Group; 2005. p.1-16.

Tuder R, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest. 2012;122:2749-55.

Fooladi A, Yazdani S, Nourani MR. Lung and systemic inflammation in COPD. In: Ong KC. (eds) Chronic Obstructive Pulmonary Disease: Current Concepts and Practice. IntechOpen, 2012.

Syed D, Afaq F, Kweon M, Bhatia N, Spiegelman V, Mukhtar H. Green tea polyphenol EGCG suppresses cigarette smoke condensate induced NF-kB activation in normal human bronchial epithelial cells. Oncogene. 2007;26:673-82.

Higashimoto, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y. Serum biomarker as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med. 2009;103:1231-8.

Ardestani, M & Zaerin, O. Role of serum interleukin 6, albumin, and C-reactive protein in COPD patients. Tanaffos. 2015;14:134-40.

Schuliga M. NF-kappaB signaling in chronic inflammation airway disease. Biomolecules. 2015;5:1266-83.

Cazzola M, Page C, Calzetta L. Emerging anti-inflammatory strategies for COPD. Eur Respir J. 2012;40:724-41.

Tabak C, Arts I, Smit H, Heederic D, Kromdout D. Chronic obstructive pulmonary disease and intake of catechins, flavonols, and flavones, the MORGEN study. Am J respir Crit Care Med. 2001;164:61-4.

Widayanto, Suradi, Setijadi A. Pengaruh furosemid inhalasi terhadap kadar interleukin-8 plasma dan skor CAT pasein PPOK eksaserbasi akut. J Respir Indo. 2015;36:1-10.

WHO. 2017. Burden of COPD. Worl Healt Organization. [Cited 2017 April 23th]. Available from: www.who.int/respiratory/copd/burden.

Fukuchi, Y. The aging lung and chronic obstructive pulmonary disease, similarity and difference. Proc Am Thorac Soc. 2009;1:570-2.

Brashier, B & Kodgule, R. Risk factors and pathophysiology of chronic obstructive pulmonary disease (COPD). Supplement to Japi. 2012;60:17-21.

Perhimpunan Dokter Paru Indonesia. Penyakit paru obstruktif kronik. Jakarta: Perhimpunan Dokter Paru Indonesia; 2016. p.1-111.

Barnes P, Celli B. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165-85.

Chung, K & Adcock, I. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008;31:1334-56.

Bailey K, Goraya J, Rennard S. The role of systemic inflammation in COPD. In: Nici L., ZuWallack R. (eds) Chronic Obstructive Pulmonary Disease: Respiratory Medicine. New Jersey: Humana Press, 2012.

Singh B, Shankar S, Srivastava R. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2012;12:1807-21.

Linder R. Serum metalloproteinase-9 is related to COPD severity and symptoms-cross-sectional data from a population baset cohort-study. Respir Res. 2015;16:28.

Kim I. Inhibition of IL-8 production by green tea polyphenols in human nasal fibroblast and A549 epithelial cells. Biol Pharm Bull. 2006;29:1120-5.

DOI: https://doi.org/10.36497/jri.v38i1.134


  • There are currently no refbacks.

Copyright (c) 2018 Jurnal Respirologi Indonesia


SINTA Garuda Indonesian Scientific Journal Database (ISJD) Indonesia One Search (IOS) Crossref

ROAD-ISSN Dimensions Google Scholar 


Jurnal Respirologi Indonesia
pISSN: 0853-7704 - eISSN: 2620-3162
Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Phone: +62-21-2247-4845
Email: editor@jurnalrespirologi.org

An official publication by
the Indonesian Society of Respirology (ISR)

Creative Commons License
Creative Commons Attribution-NonCommercial 4.0 International License